FDA Approves Merck’s Gardasil 9 for the Prevention of Certain HPV-Related Head and Neck Cancers
Print this page KENILWORTH, N.J.–(BUSINESS WIRE) June 12, 2020 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types… Read More »